Palbociclib, ribociclib, and abemaciclib are highly selective and reversible inhibitors of CDK6 that interact with the ATP binding pocket of CDK6 and form hydrogen bonds and are used for the treatment of cancer (25). This evidence concerns the gene CDK6 and cancer.